| scholarly article | Q13442814 |
| P50 | author | Jaume Alijotas-Reig | Q46803599 |
| P2093 | author name string | J Alijotas-Reig | |
| P2860 | cites work | The mechanism of the inhibitory effect of progesterone on lymphocyte cytotoxicity: I. Progesterone-treated lymphocytes release a substance inhibiting cytotoxicity and prostaglandin synthesis | Q24300042 |
| Treatment of antiphospholipid syndrome in pregnancy--a systematic review of randomized therapeutic trials | Q28171321 | ||
| Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisone plus low-dose aspirin | Q28180882 | ||
| Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies | Q28195353 | ||
| Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial | Q28218263 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Effect of Low Molecular Weight Heparins (LMWHs) on antiphospholipid Antibodies (aPL)-mediated inhibition of endometrial angiogenesis | Q28740531 | ||
| Complement and pregnancy: new insights into the immunobiology of the fetomaternal relationship | Q30877909 | ||
| Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials | Q33243658 | ||
| Complement C3 activation is required for antiphospholipid antibody-induced fetal loss | Q33340713 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| Hughes Syndrome: the antiphospholipid syndrome--a clinical overview | Q33374874 | ||
| Pregnancy and catastrophic antiphospholipid syndrome | Q33382266 | ||
| Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome | Q33630007 | ||
| Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug | Q33747286 | ||
| Successful pregnancies after combined pentoxifylline-tocopherol treatment in women with premature ovarian failure who are resistant to hormone replacement therapy. | Q34175226 | ||
| Regulation of sFlt-1 and VEGF secretion by adenosine under hypoxic conditions in rat placental villous explants | Q34429164 | ||
| Antiphospholipid thrombosis syndromes | Q34430433 | ||
| Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion | Q46696604 | ||
| Effects of Radix scutellariae and Rhizoma atractylodis on LPS-induced abortion and the uterine IL-10 contents in mice | Q46728839 | ||
| Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. | Q46886748 | ||
| Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome | Q47225448 | ||
| Low molecular weight heparin suppresses tumor necrosis factor expression from deep vein thrombosis | Q47297874 | ||
| Low-molecular-weight heparin inhibition in classical complement activation pathway during pregnancy | Q47578636 | ||
| Placental pathology in systemic lupus erythematosus: a prospective study | Q47685101 | ||
| The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a preliminary first year report | Q47705852 | ||
| Excessive exposure to anionic surfaces maintains autoantibody response to beta(2)-glycoprotein I in patients with antiphospholipid syndrome. | Q53531762 | ||
| Antiphospholipid syndrome | Q55891386 | ||
| Autoimmune Diseases Induced by TNF-Targeted Therapies | Q56907567 | ||
| Angiotensin-Converting Enzyme Inhibitors Downregulate Tissue Factor Synthesis in Monocytes | Q57398912 | ||
| High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome | Q58869486 | ||
| Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q34788539 | ||
| Management of antiphospholipid syndrome | Q34989343 | ||
| Molecular intercommunication between the complement and coagulation systems | Q35067949 | ||
| Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). | Q35101097 | ||
| A two-center study on the pharmacokinetics of intravenous immunoglobulin before and during pregnancy in healthy women with poor obstetrical histories. | Q35169322 | ||
| Resistance to annexin A5 anticoagulant activity in women with histories for obstetric antiphospholipid syndrome | Q35490209 | ||
| Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay | Q35792021 | ||
| Antiphospholipid antibodies as cause of pregnancy loss. | Q35918358 | ||
| Inflammatory response and the endothelium. | Q35928642 | ||
| Vitamin D and autoimmunity: new aetiological and therapeutic considerations | Q35954681 | ||
| Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies | Q35977256 | ||
| Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis | Q36062038 | ||
| Pathogenic role of anti-beta2-glycoprotein I antibodies on human placenta: functional effects related to implantation and roles of heparin. | Q36651142 | ||
| New targeted therapies for treatment of thrombosis in antiphospholipid syndrome | Q36998932 | ||
| Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome | Q37283036 | ||
| Tissue factor in the antiphospholipid syndrome | Q37283046 | ||
| Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature | Q37342365 | ||
| Autoimmune diseases induced by biological agents: a double-edged sword? | Q37620986 | ||
| Is obstetric antiphospholipid syndrome a primary nonthrombotic, proinflammatory, complement-mediated disorder related to antiphospholipid antibodies? | Q37664103 | ||
| The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis | Q37721612 | ||
| Towards evidence-based treatment of thrombotic antiphospholipid syndrome | Q37721614 | ||
| Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome | Q37738701 | ||
| Diagnosis and management of the antiphospholipid syndrome | Q37753513 | ||
| Lupus and pregnancy: integrating clues from the bench and bedside | Q37821052 | ||
| Pathogenesis of antiphospholipid syndrome: understanding the antibodies | Q37873720 | ||
| Intravenous immunoglobulin therapy in rheumatic diseases | Q37873722 | ||
| Management of refractory anti-phospholipid syndrome | Q37874003 | ||
| Complement and the antiphospholipid syndrome | Q37897848 | ||
| Obstetric antiphospholipid syndrome | Q37946086 | ||
| Antiphospohlipid syndrome in obstetrics | Q37955583 | ||
| Management of obstetric antiphospholipid syndrome | Q37959314 | ||
| Obstetric and vascular APS: same autoantibodies but different diseases? | Q38013583 | ||
| Heparin prevents programmed cell death in human trophoblast | Q40300623 | ||
| Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice | Q41927420 | ||
| Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients | Q41945144 | ||
| Antiphospholipid antibodies affect human endometrial angiogenesis. | Q44526752 | ||
| Successful pregnancy outcome following 19 consecutive miscarriages: case report | Q44673962 | ||
| Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation | Q45111033 | ||
| Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome | Q46179258 | ||
| Combined laparoscopic surgery and pentoxifylline therapy for treatment of endometriosis-associated infertility: a preliminary trial | Q46589939 | ||
| P433 | issue | 1 | |
| P921 | main subject | antiphospholipid syndrome | Q582207 |
| P304 | page(s) | 6-17 | |
| P577 | publication date | 2012-11-14 | |
| P1433 | published in | Lupus | Q6704846 |
| P1476 | title | Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management | |
| P478 | volume | 22 |
| Q38876334 | Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review |
| Q38410376 | Antiphospholipid syndrome: an update |
| Q33423959 | Current treatment of antiphospholipid syndrome: lights and shadows |
| Q48192268 | Detrimental roles of TNF-alpha in the antiphospholipid syndrome and de novo synthesis of antiphospholipid antibodies induced by biopharmaceuticals against TNF-alpha. |
| Q33413002 | Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis |
| Q38826804 | Immunotherapeutic strategies in antiphospholipid syndrome |
| Q87774110 | Management of very high risk pregnancy with secondary anti-phospholipid syndrome and triple positivity to the anti-phospholipid antibodies |
| Q26998188 | Obstetrical antiphospholipid syndrome: from the pathogenesis to the clinical and therapeutic implications |
| Q38891094 | Pregnancy Outcome in Women with Obstetric and Thrombotic Antiphospholipid Syndrome-A Retrospective Analysis and a Review of Additional Treatment in Pregnancy. |
| Q38175887 | Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment? |
| Q34462726 | Recurrent miscarriage: causes, evaluation and management |
| Q36043513 | Response to Plasmapheresis Measured by Angiogenic Factors in a Woman with Antiphospholipid Syndrome in Pregnancy |
| Q53101748 | Thrombophilia and Pregnancy |
| Q39039141 | Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review |
| Q35915182 | Unexplained Recurrent Miscarriage and Recurrent Implantation Failure: Is There a Place for Immunomodulation? |
Search more.